EASL Podcasts

Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Education at the heart of EASL’s missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - SLD nomenclature: Need for refinement?FacultyAleksander Krag (Moderator)Meena Bansal (Faculty)Sven Francque (Faculty)Alexandre Louvet (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Exploring new frontiers: The AI liver taskforce initiativeFacultyEric Trépo (Moderator)Tom Lüdde (Faculty)Jakob Kather (Faculty)Raquel Pérez-López (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Advances in systemic treatments in liver cancerFacultyJosep Llovet (Moderator)Massimo Iavarone (Faculty)Matthias Pinter (Faculty)Jessica Zucman-Rossi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.FacultyAleksander Krag (Moderator)Debbie Shawcross (Faculty)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.FacultyThomas Berg (Moderator)Jordan Feld (Faculty)Norah Terrault (Faculty)Heiner Wedemeyer (Faculty)This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.Related episodesSeason 6, Episode 2: Why do we need HBV functional cure?Season 5, Episode 8: JHEP Live: Hepatitis Delta’s Latest Debate: Updates Straight from EASL’s SlateSeason 5, Episode 3: Zoonotic Hepatitis E: What’s hot in 2023?EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challengesSeason 4, Episode 19: HDV: The devil becomes treatableSeason 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?All EASL Studio Podcasts are available on EASL Campus.

This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.To learn even more about endoscopic procedures in hepatology, take a look at this study by Wim Laleman et al., published in January 2024 in the Journal of Hepatology.Faculty Wim Laleman (Moderator)Andres Cardenas (Faculty)Gavin Johnson (Faculty)Reem Sharaiha (Faculty)Related episodesSeason 6, Episode 11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?Season 3, Episode 15: Chronic portal vein thrombosis: anticoagulation and interventional radiology for all patients?Season 2, Episode 14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureSeason 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease AwarenessSeason 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizonAll EASL Studio Podcasts are available on EASL Campus.